Bortezomib: an effective agent in extramedullary disease in multiple myeloma

European Journal of Haematology
Rosiñol LauraEmili Montserrat

Abstract

Bortezomib is a potent and selective proteasome inhibitor recently introduced in the treatment of multiple myeloma (MM). This drug produces significant responses in about one-third of patients with relapsed/refractory disease. We first recognized the lack of efficacy of thalidomide in soft-tissue plasmacytomas. There is little information on the effect of bortezomib on extramedullary myeloma. Four of 23 patients treated with bortezomib at our institution had extramedullary involvement at the time of relapse. In three of these patients large soft-tissue plasmacytomas disappeared. This indicates that bortezomib may be useful in clinical situations of extramedullary disease in which other agents, such as thalidomide, may not be effective.

References

Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BladéR A Kyle
Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Jun 14, 2001·British Journal of Haematology·J BladéE Montserrat
Oct 24, 2002·Blood·Shaji KumarS Vincent Rajkumar
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Donna WeberRaymond Alexanian
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Apr 6, 2004·Leukemia & Lymphoma·Athanasios AnagnostopoulosMeletios Athanasios Dimopoulos
May 29, 2004·The Hematology Journal : the Official Journal of the European Haematology Association·Wai M LiuJames S Malpas
Oct 6, 2004·British Journal of Haematology·S JagannathK C Anderson
Jan 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vincent RajkumarKenneth C Anderson
Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators

❮ Previous
Next ❯

Citations

Jun 26, 2008·Annals of Hematology·Y Y HwangT Yau
Aug 7, 2010·Annals of Hematology·Hong-Yan LvJin-Qiao Zhang
Jun 8, 2011·Annals of Hematology·Tomonori NakazatoYoshinobu Aisa
Aug 17, 2011·Journal of Gastrointestinal Cancer·Rodrigo Lopes da Silva
Dec 14, 2011·Advances in Therapy·Beatriz AguadoAlbert Oriol
Dec 14, 2011·Advances in Therapy·Albert Oriol
Jul 28, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M VarettoniM Lazzarino
Sep 19, 2006·European Journal of Haematology·M Teresa CibeiraJoan Bladé
Apr 9, 2011·Case Reports in Oncology·Soo-Young BaeJe-Jung Lee
Nov 6, 2012·Haematologica·Joan BladéLaura Rosiñol
Mar 5, 2009·Annals of Hematology·A SiniscalchiT Caravita
Feb 7, 2009·Leukemia & Lymphoma·Ping WuGareth J Morgan
Dec 6, 2012·Leukemia & Lymphoma·Matthew Weinstock, Irene M Ghobrial
Jun 23, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Binay Kumar Shah, Anup Shrestha
Feb 5, 2014·Journal of Voice : Official Journal of the Voice Foundation·Yijin Jereme GanJeevendra Kanagalingam
Oct 14, 2011·Leukemia Research·Alessandro GozzettiFrancesco Lauria
Sep 25, 2010·Cancer Treatment Reviews·Niels W C J van de DonkAntonio Palumbo
Oct 10, 2008·Leukemia Research·Silvia MangiacavalliAlessandro Corso
Jun 15, 2007·Clinical Lymphoma & Myeloma·Alessandro GozzettiFrancesco Lauria
Jan 18, 2008·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Oscar BergesYoulia M Kirova
Dec 22, 2007·European Journal of Radiology·Markus WeiningerMatthias Beissert
Jun 15, 2007·La Revue de médecine interne·C Hulin
Mar 17, 2009·European Journal of Haematology·Cyrus ChargariAlain Fourquet
Aug 12, 2008·European Journal of Haematology·Muralikrishnan SrikanthGareth J Morgan
Dec 23, 2011·Journal of Digestive Diseases·Rodrigo Lopes da Silva
Aug 1, 2012·The Journal of Obstetrics and Gynaecology Research·Behrang KazeminezhadSara Zahedifard
May 12, 2011·European Journal of Haematology·José M Calvo-VillasUNKNOWN GEM-PETHEMA/Spanish Myeloma Group, Spain
Mar 24, 2016·Hematology/oncology and Stem Cell Therapy·Panagiotis J VlachostergiosRajeev L Balmiki
Apr 17, 2015·Journal of Medical Case Reports·Saskia E M Schols, Lidwine L W Tick
Jan 15, 2015·Blood·Joan BladéCarlos Fernández de Larrea

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.